CD274 and non-small cell lung carcinoma: PD‐L1 expression status was available for 19 of 35 (54.3%) SQ NSCLC patients, and the proportions of patients with PD‐L1 expression <1%, 1%–<50%, and ≥50% were 21.1%, 52.6%, and 26.3%, respectively (Table 1).